Retapamulin

Brand names: Altabax · Active ingredient: Retapamulin

In short: ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolate

Forms & strengths10 mg retapamulin/1g of ointment in 5, 10, 15, and 30 gram tubes
LabelPhysicians Total Care, Inc.
Label updatedOct 09, 2010

What is Retapamulin used for?

ALTABAX is indicated for use in adults and pediatric patients

aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in

pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates

only) or Streptococcus pyogenes

.

To reduce the development of drug-resistant bacteria and maintain the

effectiveness of ALTABAX and other antibacterial drugs, ALTABAX should

Retapamulin dosage

A thin layer of ALTABAX should be applied to the affected area (up to 100

cm2 in total area in adults or 2% total body surface area

in pediatric patients aged 9 months or older) twice daily for 5 days. The

treated area may be covered with a sterile bandage or gauze dressing if desired

.

How to take Retapamulin — instructions & advice from the label

Patients using ALTABAX and/or their guardians should receive the

following information and instructions: Use ALTABAX as directed by the

healthcare practitioner. As with any topical medication, patients and caregivers

should wash their hands after application if the hands are not the area for

treatment.

ALTABAX is for external use only. Do not swallow ALTABAX or use it in the

eyes, on the mouth or lips, inside the nose, or inside the female genital area.

The treated area may be covered by a sterile bandage or gauze dressing, if

desired. This may also be helpful for infants and young children who

accidentally touch or lick the lesion site. A bandage will protect the treated

area and avoid accidental transfer of ointment to the eyes or other areas.

Use the medication for the full time recommended by the healthcare

practitioner, even though symptoms may have improved.

Notify the healthcare practitioner if there is no improvement in symptoms

within 3 to 4 days after starting use of ALTABAX.

ALTABAX may cause reactions at the site of application of the ointment. …

Warnings & precautions

Do not take this medicine if: None.

In the event of sensitization or severe local irritation from

ALTABAX, usage should be discontinued, the ointment wiped off, and appropriate

alternative therapy for the infection instituted .

ALTABAX is not intended for ingestion or for oral, intranasal,

ophthalmic, or intravaginal use. ALTABAX has not been evaluated for use on

mucosal surfaces .

The use of antibiotics may promote the selection of

nonsusceptible organisms. Should superinfection occur during therapy,

appropriate measures should be taken.

Prescribing ALTABAX in the absence of a proven or strongly suspected

bacterial infection is unlikely to provide benefit to the patient and increases

the risk of the development of drug-resistant bacteria.

Retapamulin side effects

The safety profile of ALTABAX was assessed in 2,115 adult and

pediatric patients ≥9 months who used at least one dose from a 5-day, twice a

day regimen of retapamulin ointment. Control groups included 819 adult and

pediatric patients who used at least one dose of the active control (oral

cephalexin), 172 patients who used an active topical comparator (not available

in the US), and 71 patients who used placebo.

Adverse events rated by investigators as drug-related occurred in 5.5%

(116/2,115) of patients treated with retapamulin ointment, 6.6% (54/819) of

patients receiving cephalexin, and 2.8% (2/71) of patients receiving placebo.

The most common drug-related adverse events (≥1% of patients) were application

site irritation (1.4%) in the retapamulin group, diarrhea (1.7%) in the

cephalexin group, and application site pruritus (1.4%) and application site

paresthesia (1.4%) in the placebo group.

Because clinical studies are conducted under varying conditions, adverse

reaction rates observed in the clinical studies of a drug cannot be directly

compared to rates in the clinical studies of another drug and may not reflect

the rates observed in practice. The adverse reaction information from the

clinical studies does, however, provide a basis for identifying the adverse

events that appear to be related to drug use and for approximating rates. …

Drug interactions

Co-administration of oral ketoconazole 200 mg twice daily

increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment,

1% on the abraded skin of healthy adult males. Due to low systemic exposure to

retapamulin following topical application in patients, dosage adjustments for

retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as

ketoconazole. Based on in vitro P450 inhibition studies and the low systemic

exposure observed following topical application of ALTABAX, retapamulin is

unlikely to affect the metabolism of other P450 substrates.

The effect of concurrent application of ALTABAX and other topical products to

the same area of skin has not been studied.

About this medicine

ALTABAX contains retapamulin, a semisynthetic pleuromutilin antibiotic. The

chemical name of retapamulin is acetic acid, [[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester. Retapamulin, a white to

pale-yellow crystalline solid, has a molecular formula of C30H47NO4S, and a

molecular weight of 517.78. The chemical structure is:

Each gram of ointment for dermatological use contains 10 mg of retapamulin in

white petrolatum.

How it works: ALTABAX is an antibacterial agent . In post-hoc analyses of manually over-read 12-lead ECGs from healthy subjects (N = 103), no significant effects on QT/QTc intervals were observed after topical application of retapamulin ointment on intact and abraded skin. Due to the low systemic exposure to retapamulin with topical application, QT prolongation in patients is unlikely .

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9fae06b5-bbd5-400a-a7a6-3a4e238361f8. Read the full official label on DailyMed.